Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907854 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 407
- Enrollment target
NCT01907854 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 407 participants.
The verdict
NCT01907854, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 407 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2013-12-02 |
| Est. Completion | 2015-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01907854
The ClinicalTrials.gov registry entry for NCT01907854 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01907854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01907854 about?
NCT01907854 is a clinical study titled "Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin". This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.
What is the current status of trial NCT01907854?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 407 participants. The study started on 2013-12-02. Estimated completion is 2015-06-15.
What interventions are being tested in trial NCT01907854?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01907854?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.